BC Extra | Sep 5, 2019
Preclinical News

2016 study on gut integrin HIV target can't be replicated

Three preclinical studies and one clinical trial could not replicate the antiviral effects of an antibody against α4β7 to treat HIV or simian immunodeficiency virus, casting doubt on a theory that preventing CD4+ T cells...
BC Week In Review | Nov 2, 2018
Company News

Takeda proposes divestment of Shire GI candidate, announces loans

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647 once it completes its acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). The move...
BioCentury | Sep 28, 2018

Morphic reloads

With Morphic Therapeutic’s second integrin program running ahead of schedule, the company has raised an $80 million series B round to sustain its current development pace. Existing investor Omega Funds and new investor Novo Holdings...
BC Extra | Sep 25, 2018
Financial News

Morphic's $80M round paves way for integrin clinical studies

Morphic Therapeutic (Waltham, Mass.) raised $80 million in a series B round led by existing investor Omega Funds and new investor Novo Holdings A/S (Hellerup, Denmark). New investors Invus and EcoR1 Capital, and existing investors...
BC Week In Review | Aug 17, 2018
Clinical News

New Phase IIb analyses support further development of Protagonist's UC candidate

Protagonist Therapeutics Inc. (NASDAQ:PTGX) said new analyses from the discontinued Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis showed that the initial findings by an IDMC were "an unfortunate consequence...
BC Week In Review | Aug 3, 2018
Clinical News

Takeda's subcutaneous Entyvio meets in Phase III for maintenance therapy of ulcerative colitis

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said subcutaneous Entyvio vedolizumab as maintenance therapy met the primary endpoint vs. placebo in the Phase III VISIBLE 1 trial to treat ulcerative colitis in patients who achieved a clinical...
BC Week In Review | Mar 30, 2018
Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate...
BC Extra | Mar 26, 2018
Clinical News

Protagonist shares halved on UC failure

Protagonist Therapeutics Inc. (NASDAQ:PTGX) was down $11.68 (57%) to $8.75 on Monday after the company discontinued the Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide...
BC Innovations | Feb 21, 2018
Distillery Techniques


TECHNOLOGY: Plasma markers The pre-HIV infection fraction of CD4 + T cells expressing integrin α 4 β 7 could help predict susceptibility to HIV infection. In 70 of 206 at-risk women from South Africa and...
BC Week In Review | Dec 1, 2017
Company News

Takeda, Portal partner to develop needle-free biologics

Portal Instruments Inc. (Cambridge, Mass.) partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to develop and commercialize Portal’s needle-free drug delivery device for use with Takeda’s investigational and approved biologics. The device delivers biologics through a...
Items per page:
1 - 10 of 95